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ABSTRACT 
INTRODUCTION: Due to the progressive nature of type 2 diabetes, its complexity and drug 
treatment perpetuity, there is currently a search for surgical procedures that can promote 
euglycemia also in non-obese patients. Diabetic patients glycemic control can be achieved by 
increasing the blood concentration of GLP-1, a hormone produced by L cells that are more 
densely concentrated in the terminal ileum. Early and extended improvement of diabetes in 
patients submitted to bariatric surgeries awakened the necessity of investigating the isolated 
ileal interposition as surgical alternative for the treatment of diabetes. The interposition of this 
ileal segment to a more anterior region (proximal jejunum) can promote a greater stimulation 
of the L cells by poorly digested food, increasing the production of GLP-1 and reflecting on 
glycemic control. However, in order to consolidate the ileal interposition as a surgical 
treatment of diabetes it is necessary that the interposed ileum keep the same differentiation 
rate into L cells for a long period to justify the intervention.  
AIMS: To investigate the isolated ileal interposition influence on the differentiation of 
intestinal precursor cells into enteroendocrine L cells over time.  
METHODS: Twelve 12-week-old male Wistar rats (Rattus norvegicus albinus) of the WAB strain 
(heterogeneous) will be used. All animals will receive a high-calorie, high-fat diet for 16 weeks 
or more until they develop glucose dysmetabolism confirmed by glycemic test. They will be 
divided into two groups of 10 animals each: the isolated ileal interposition group (GI) and the 
control group (GC), comprising animals that will not be submitted to any surgical intervention. 
Blood samples will be collected under anesthesia at the weeks 12, 26, 36 and 44 for the 
determination of serum levels of glucose, insulin, GLP-1, glucagon, C-peptide and glycosilated 
hemoglobin. The insulin tolerance test will be performed and insulin resistance will be 
calculated. For the comparative analysis of the ileal precursor cells differentiation into 
enteroendocrine cells among the two groups, the following intestinal fragments will be 
collected after euthanasia: interposed ileum and remaining ileum from GI, jejunum and ileum 
from GC. These fragments will be analyzed by imunofluorescence and also by Real Time PCR 
using PCR Arrays for target genes including the main ones related to stem cell, stem cell 
singnalling, diabetes, Wnt and Notch signaling pathways and other genes and pathways 
involved in the differentiation of intestinal precursor cells into enteroendocrine cells, 
especially GLP-1-producing L cells that play important role in euglycemia.               
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1. INTRODUCTION 
Diabetes is one of the most common chronic diseases and a growing global epidemic 
(Danaei et al., 2011).1 Type 2 diabetes (T2D) is a serious metabolic disease characterised by 
high glucose levels. Complications from T2D usually result in poor quality of life, disability, and 
early death.2 Despite efforts to control glycaemia in diabetes patients, no therapeutic 
approach has significantly impacted the progression of this disease (Tahrani et al., 2010).3 
There is, however, a simple and reversible surgical procedure that might become a valid 
therapeutic alternative in non-obese patients. This procedure, isolated ileal interposition (III), 
results in a dramatic increase in the incretin glucagon-like peptide 1 (GLP-1). 
Epidemiology and aetiopathogenesis of diabetes  
In 2000, diabetes caused the death of about three million people.4 In 2010, the number of 
affected individuals was approximately 285 million, and this number is projected to increase 
54% by 2030. A much greater increase in the number of adults with diabetes is projected in 
underdeveloped countries than in developed countries: the number of affected individuals is 
projected to increase approximately 70% in underdeveloped countries and 20% in developed 
countries.1 T2D, also known as non-insulin-dependent diabetes, is responsible for 90% to 95% 
of diabetes cases.5 
T2D is a progressive heterogeneous disease that mainly involves peripheral insulin 
resistance and gradual dysfunction of pancreatic beta cells.2,6 It develops when pancreatic 
islets can no longer maintain insulinaemia at levels sufficient to overcome peripheral tissue 
resistance. Throughout the course of the disease, diabetes passes through intermediate 
stages. Initially, diabetes is treated only with modifications in lifestyle and specific diet. Later in 
the disease, patients are treated with drugs that promote insulin secretion. As insulin 
deficiency unavoidably increases, however, the combination of therapeutic oral agents often 
fails to control hyperglycaemia efficiently, and the use of insulin is eventually required.6-9 
In the long run, patients with T2D have an increased risk of complications that are a 
substantial cause of morbidity and mortality, including macrovascular disease, nephropathy, 
retinopathy, and neuropathy.10 Further complications of diabetes include ischemia of the limbs 
resulting in amputation, dental problems, and pregnancy disorders.5 The risk of developing 
diabetes-associated complications is related to the duration of diabetes and the level of 
glycaemic control.11 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.6
61
4.
2 
: P
os
te
d 
30
 N
ov
 2
01
1
 
 
Although 90% of T2D cases can be attributed to excessive weight,12 its incidence is growing 
among individuals with body mass index (BMI) in the normal and overweight ranges.13,14 
Treatment of diabetes 
T2D is a multifaceted condition requiring an integrated and individualised approach to 
each patient’s care that can prove quite challenging (Freeman, 2010).15 Treatment must 
initially be based on substantial lifestyle changes, including diet adjustment and regular 
physical activity. In most patients, these behavioural measures eventually do not suffice to 
keep glycaemia within appropriate levels, and oral antidiabetic agents are added.17 Currently, 
there are several drug classes with different mechanisms of action that might be used singly or 
in various therapeutic combinations.16 Many patients eventually require combinations of two 
or more oral drugs.17-19 Despite these treatments, glycaemia increases over time as the disease 
progresses, requiring the use of insulin in combination with oral agents and eventual full 
insulinisation. Although these interventions might decrease peripheral blood glycaemia, none 
of these actions is effective in stopping disease progression.9 Intensification of insulin therapy 
is the most appropriate intervention used to attempt to achieve normoglycaemia and reduce 
complications through early, strict, persistent, and effective control of glycaemia.16,20,21 Thus, 
insulin is currently the only effective conservative therapeutic option for achieving metabolic 
control.6,7,22 
However, the use of external insulin is not easy to manage. Attaining optimal 
glycaemic levels, i.e., glycaemia levels as close as possible to those of a non-diabetic 
individual23 in order to prevent complications, still poses a major challenge in clinical 
practice.2,21 Due to the limitations of most of the available therapeutic measures, only a small 
fraction of the diabetic population meets therapeutic goals.23 These limitations include poor 
compliance with diets, resistance to physical exercise programmes, limited efficacy and 
significant side effects of current therapeutic agents, delays in insulin therapy onset, and 
patient aversion to the multiple parenteral injection regimes required for the administration of 
insulin.21-24 Successful insulin therapy requires accurate information, motivation, high 
socioeconomic and cultural levels, high adherence and learning ability, availability of 
resources, and participation of and support by a multiprofessional team. 
Some antidiabetic drugs accelerate beta cell apoptosis,2 whereas others reduce bone 
mineral density and promote weight gain due to volume expansion and oedema, potentially 
causing or exacerbating heart failure and triggering ischemic cardiac events.17,18 Some insulin 
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analogues are associated with a more physiological pattern of recovery; these drugs are more 
flexible to use and convenient to prescribe, and they allow greater freedom in diet while still 
providing improved quality of life.6,7,25Formulations eliminating the need for subcutaneous 
injections might correct some limitations of typical insulin therapy, thus improving glycaemic 
control and increasing patient quality of life.21 Some formulations that allow non-invasive 
administration of insulin are in the testing phase, including the inhalable insulin powders 
Exubera (Pfizer), Technosphere (MannKind), Aerdose (Aerogen), BAI (Kos), Alveair (Coremed), 
and Bio-Air (BioSante). Therapy selection must take into account tolerability, non-glycaemic 
effects of antidiabetic agents, effects on associated comorbidities, and cost (Stolar et al., 
2008).17  
The limitations of conventional treatments that fail to preserve pancreatic beta cell 
function over time have resulted in a critical need to find new means to attain appropriate 
glycaemic control and avoid or delay the need for additional measures (Hansen et al., 2010).2 
Thus, antidiabetic treatments seeking to preserve beta cell function and integrity and halt T2D 
progression are clearly needed.8 More effective measures based on the disease 
aetiopathogenesis are necessary; these measures must control both fasting and postprandial 
glycaemia.22 
A new approach to T2D treatment involves the use of therapies based on incretins 
such as dipeptydil peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists, which are GLP-1 
analogues and bind to GLP-1 receptors on pancreatic beta cells to inactivate them.2,3 Both 
groups of drugs have proven safe and effective in reducing glycaemia and have yielded 
favourable effects regarding weight, lipid profile, and blood pressure.9,17,26-28 Both are 
associated with insulin release and glucose-dependant glucagon suppression with consequent 
low hypoglycaemia risk. Experimental studies showed that these therapies prolong the 
survival, delay the dysfunction, and promote the regeneration of pancreatic beta cells and thus 
theoretically hold the potential to halt T2D progression.3,9,28 
Although these studies have demonstrated the therapeutic promise of DPP-4 and GLP-
1 analogues, the high cost of these new agents and the lack of studies on their long-term 
safety must be considered. Nausea, headache, acute pancreatitis, upper airway infection, 
depression, severe hypoglycaemia, and skin allergic reactions have been reported with the use 
of these drugs. Some individuals also exhibit moderate reduction of glycated haemoglobin 
levels when compared to patients treated with insulin and older agents. Moreover, the 
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development of carcinomas has been associated with the use of these agents in guinea pigs; 
however, this finding has not been confirmed in humans.18,19,28 
In addition to the wide variety of pharmacological options for multidisciplinary 
treatment aimed at weight loss and glycaemic control, bariatric and metabolic surgical 
techniques can be included among the therapeutic approaches to T2D and insulin resistance. 
These surgical interventions have been shown to provide long-term control of T2D.29,30  
Surgical interventions 
Bariatric surgery can improve and eventually completely reverse obesity-associated 
comorbidities in 70% to 100% of patients,31 thus increasing their life expectancy,32 partially 
reversing hypothalamic dysfunction, and increasing the anti-inflammatory activity of the 
cerebrospinal fluid.33 
Improved glycaemic control is observed months after adjustable gastric band surgery, 
and improvement is faster and more complete with ROUX-en-Y bypass. Both strategies can 
improve or even cure T2D, potentially through different mechanisms (Meijer et al., 2011).34 
Vertical gastrectomy with or without contention ring and Roux-en-Y gastrojejunal bypass – 
thought to be the gold standard surgical intervention in the treatment of morbid obesity – are 
known to achieve the goals of weight loss and control of comorbidities and to maintain these 
goals over time.35 This control of comorbidities is usually attributed to body mass reduction; 
however, a potentially glycaemia-controlling endocrine effect has been observed even before 
any significant weight loss.36 After gastrojejunal bypass, levels of substances directly secreted 
by the bowel such as GLP-1 were found to be elevated in the peripheral blood; these 
substances can stimulate insulin production by pancreatic beta cells, facilitate insulin-mediated 
glucose transport into cells, and induce a feeling of satiety.37 
Roux-en-Y gastrojejunal bypass favours the stimulation of GLP-1-producing cells by 
foods arriving at the distal portions of the small intestine incompletely digested, as food transit 
is diverted to the proximal jejunum.38 Jejunal bypass and other highly effective bariatric and 
metabolic surgical interventions deliver nutrient-rich chyme to the distal bowel earlier than 
normal. Its arrival directly to the ileum activates a negative feedback mechanism known as the 
“ileal brake”,39 which involves neuronal and endocrine mechanisms that influence stomach 
voiding, intestinal motility, and satiety.40 
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As early as 1998, it was already thought that T2D might be an anterior bowel disease.41 
Currently, several clinical, physiological, biological, anthropological, epidemiological, 
anatomical, and evolutionary lines of evidences together with surgical results have confirmed 
that the proximal small intestine – whose size was appropriate for our ancestral environment – 
might have become too large due to the modern industrialised diet. Consumers of a rich and 
modified modern diet developed a much larger anterior intestine (jejunum) than desired. A 
shorter jejunum prevent ingested food from being fully absorbed in the proximal portion of 
the intestine, allowing it to arrive at the distal intestine (ileum) almost in natura in order to 
stimulate L-type endocrine cells to produce substances such as GLP-1 that promote insulin 
production by the endocrine pancreas, facilitate glucidic metabolism in peripheral tissues, and 
induce satiety through selective hypothalamic inhibition.42 
The genesis of disruptions in glucose metabolism involves a multifaceted range of 
intimately intertwined factors. Of these factors, hormones are the most significant; of 
particular interest is GLP-1, which is produced by enteroendocrine L-cells of the small intestine, 
which are more densely concentrated at the terminal ileum.32 GLP-1 is produced by tissue-
specific post-translational processing of its precursors, namely, the peptide proglucagon, by 
pro-hormone convertase enzymes.43 Post-translational modifications of the glucagon gene give 
rise to five different products in the bowel: glycentin, oxyntomodulin (OXM), intervening 
peptide-1 (IP-1), GLP-1, and GLP-2.44 Proglucagon is processed in bowel L-cells by PC1/3 pro-
hormone convertase.43 GLP-1 secretion occurs in response to stimuli generated by nutrients 
with an incretin effect.45 Incretins are hormones secreted into the blood circulation by the 
gastrointestinal tract in response to intake of certain nutrients. This results in increased insulin 
production and consequent glucose uptake. GLP-1 has well-defined functions, such as 
stimulation of glucose-dependent insulin secretion, upregulation of insulin gene transcription, 
induction of Langerhans islet beta cell neogenesis and proliferation, inhibition of beta cell 
apoptosis, increased phenotypic differentiation of beta cells, stimulation of somatostatin 
production, and reduction of glucagon production.46,47 
Advances in neurogastroenterology have provided a better understanding of 
gastrointestinal physiology. Therefore, bariatric surgery intervention modalities evolved into 
the current mixed procedures that take into account neurohormonal and metabolic factors in 
addition to restriction and dysabsorption features. Thus, the term baroendocrine surgery is 
increasingly used, especially in the treatment of T2D.38,40 Currently, mixed (restrictive and 
dysabsorptive) bariatric surgery is the most efficacious treatment in patients with morbid 
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obesity, resulting in significant improvement of associated comorbidities (Melissas, 2008).49 In 
studies of these interventions, enhanced GLP-1 release and improved glycaemic control have 
been observed even before significant weight loss, demonstrating that the control of diabetes 
might be related to hormonal effects secondary to the surgical technique performed.47,50 
Isolated ileal interposition 
In the early 1980s, enhanced GLP-1 release had already been shown to suffice for body 
weight control in obese rats treated with the interposition of a 5- or 10-cm terminal ileum 
fragment.51 The effects of this surgery are illustrated in Figure 1. 
 
 
Figure 1. Effects of ileal interposition on glucose control. (1) Dietary nutrients enter the bowel lumen and stimulate 
neuroendocrine cells causing (2) early and long-lasting GLP-1 release, (4) which will affect gastrointestinal motility 
and stomach voiding. (5) GLP-1 is an incretin and will also mediate insulin secretion and endocrine pancreas 
protection.
52
 
 
Another study in rats showed hypertrophy of transposed ileum together with 
increased serum GLP-1 levels.53 In humans, GLP-1 increased after jejunoileal and 
biliopancreatic bypass in morbidly obese individuals.54 Another study published in 1998 
showed that patients exhibited high levels of GLP-1 even 20 years after jejunoileal bypass.55 
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Together with a study published in 1999, these findings suggested that ileal interposition might 
be used as a treatment for T2D.56 Fast and permanent improvements in glucose control were 
observed in patients immediately after bariatric surgery, and surgery eliminated the need for 
glycaemia-controlling drugs in most cases.57,58 The beneficial effects of bariatric surgery on 
glycaemic control also depend on the duration of disease59 and the type of surgical 
intervention; interventions based solely on stomach restriction, such as adjustable gastric 
bands, proved to be less effective in improving T2D than procedures involving substantial 
amounts of intestinal bypass55,60,61 or significant increases in digestive transit speed, such as 
vertical gastrectomy.62,63 
Vertical gastrectomy is aimed mainly at achieving weight loss. It is a restrictive 
procedure due to the significant reduction in stomach reservoir capacity; moreover, it is 
considered a metabolic procedure, as it results in reduced circulating levels of the orexigenic 
hormone ghrelin, which is produced at the fundus and greater curvature of the stomach.62,63 
The good long-term postoperative64 glycaemic control achieved by vertical gastrectomy63 
might be due to the arrival of incompletely digested food at the distal ileum as a result of 
increased voiding speed after surgery, which in turn results in increased GLP-1 secretion by L-
cells.66 
Ileal interposition has frequently been performed in obese and non-obese humans; 
however, it is never performed in isolation. Promising results were recently obtained in 
humans using techniques combining vertical gastrectomy with the interposition of a segment 
of distal ileum in the trajectory of the proximal jejunum.67-72 This procedure can induce early 
satiety along with benefits to glucidic metabolism and cause short- and long-term weight loss. 
In non-obese diabetic patients, vertical gastrectomy combined with ileal interposition 
effectively controlled T2D.67-71 Analysis of the effects of vertical gastrectomy combined with 
ileal interposition on humans 6 and 18 months after the procedure demonstrated T2D 
remission in 80% of patients, who were freed from treatment with hypoglycaemic agents or 
diet. The remaining 20% of patients showed significant improvement despite the need to 
continue oral treatment (Tinoco, 2011).72 
Despite these findings, however, there is a conceptual problem in proposing to 
perform vertical gastrectomy in non-obese diabetic patients: the metabolic benefits reported 
in the literature67-22 were probably due almost exclusively to ileal interposition rather than to 
the partial gastric restriction procedure (vertical gastrectomy). 
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The early postoperative improvement in glucose metabolism observed in obese and 
diabetic patients subjected to vertical gastrectomy alone63 is most likely due to the increase in 
intestinal transit speed induced by intervention,66 which favours quicker arrival of undigested 
food to the terminal ileum, where it stimulates L-cells to produce endogenous GLP-1. We 
conclude that in these non-obese patients with glucidic dysmetabolism, vertical gastrectomy 
improves glucose metabolism, but this effect is only due to the acceleration of gastrointestinal 
transit, which causes incompletely digested food to arrive at the terminal ileum, where it 
triggers GLP-1 production by L-cells. Other consequences of vertical gastrectomy, such as the 
restriction caused by making the gastric reservoir a small-calibre tube, and the anorexigenic 
effect caused by reducing levels of the orexigenic hormone ghrelin,63 arise from the removal of 
the fundus and greater curvature of the stomach, where X/A-type neuroendocrine cells are 
more concentrated. However, vertical gastrectomy is a major surgical procedure that is not 
without significant complications, such as torpid evolution of fistulas and reflux esophagitis. 
There is no reason to apply this procedure to non-obese diabetic patients, in whom isolated 
ileal interposition may be highly effective. Ileal interposition in rats involves placing a 10- to 20-
cm segment of distal ileum with its nerves and vessels intact into the proximal jejunum,73 
resulting in significant hyperplasia, hypertrophy, and even full “jejunisation” of the transposed 
ileum.74-78 
Isolated ileal transposition proved efficacious in correcting dysmetabolism in several 
studies of experimental animals;51,79,80 however, in the context of bariatric and metabolic 
surgery, this surgical modality involving only ileal interposition has not been assessed in 
humans. 
Increased synthesis and release of GLP-1 can be attributed to increased stimulation of 
L-cells located in the interposed ileum segment in response to the presence of a greater 
amount of partially digested food, resulting in direct effects on glucidic metabolism (Patriti et 
al., 2007).81 Serum levels of GLP-1 increase in response to alimentary stimulation, resulting in a 
satiating effect on the central nervous system,82 reduced fat absorption by the gastrointestinal 
tract,83 and reduced gastric84 and intestinal motility.85 The most remarkable effects of GLP-1 
are reduced peripheral insulin resistance, decreased apoptosis of pancreatic beta cells, 
increased differentiation of primitive pancreatic canaliculus cells into adult beta cells, and 
increased proliferation of beta cells.86,87 
GLP-1 is the incretin hormone most associated with the antidiabetic effects of bariatric 
surgery. Stimulation of ileal L-cells to cleave proglucagon and release GLP-1 seems to be the 
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most effective means of inducing the incretin effect in diabetic patients subjected to bariatric 
surgery. Several techniques might be applied to achieve this effect. All of these techniques are 
derived from the hindgut theory, which states that contact of partially digested food with the 
ileum corrects the deleterious effects of “empty ileum syndrome” caused by the lack of L-cell 
stimulation.61,81,88 The results of the simple interposition of an ileum segment into the proximal 
segments of the small intestine are the strongest arguments supporting this hypothesis. A 
study of interposition in experimental animals subjected to a model of diet-induced obesity 
showed a significant increase in GLP-1 levels (Strader, 2006).52 Similarly, interposition of a 50-
cm ileum segment distal to Treitz’s angle in combination with vertical gastrectomy resulted in 
improved diabetes symptoms in a clinical trial.89 
In addition to the “ileal brake” (a reaction that decreases proximal gastrointestinal 
transit motility and enterohormone90,91 production following ileal interposition surgery), ileal 
interposition also improved glucose tolerance in experimental, euglycaemic rats.52,92 
These findings suggest that isolated ileal interposition might be a valid alternative for 
the treatment of diabetes. Due to the intestines’ great capacity for adaptation, further 
research is necessary to justify ileal interposition as a surgical treatment for diabetes. 
Specifically, studies addressing the ability of interposed ileum L-cells to continue to 
differentiate with a density similar to intact ileum; to fulfil their functions, including GLP-1 
production, over time; and to contribute to the metabolic control of glucose levels will be 
necessary.  
Cell differentiation and intestinal adaptation 
Cells of the small intestine constantly proliferate and differentiate, and they are able to 
adapt after injury, inflammation, or resection.93 The intestine is known to be able to adapt 
morphologically and functionally in response to internal and external stimuli. Intestinal 
adaptation, also known as enteroplasticity, is a complex and multifaceted process that serves 
as a paradigm for gene-environment interactions. Adaptation can occur after the loss of a 
small portion of intestine, in diabetes, with age, or due to malnutrition.94-97 Increased nutrient 
absorption after intestinal resection compensates for absorption surface loss and minimises 
malabsorption98 by increasing crypt depth, villus length, enterocyte proliferation, and 
absorption of electrolytes, glucose, and amino acids.99,100 
Several studies aiming to elucidate the basis of the adaptation response showed that 
digestive and absorptive properties are increased coordinately with the expression of 
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enteroendocrine genes.101-103 Peptides derived from proglucagon, an adaptation response 
marker, act as humoural mediators; ileal levels of proglucagon increase after small intestine 
resection. Proglucagon messenger RNA (mRNA) levels increase specifically in the ileum. This 
increase is immediate and persists for up to three weeks after resection.104 Multiple complex 
factors, including humoural factors such as the growth factors insulin-like growth factor 1 (IGF-
1), peptide YY (PYY), epidermal growth factor (EGF), and GLP-2, biliopancreatic secretions, and 
nutritional factors (glutamine, arginine, fatty acids, and triglycerides), also influence the 
mechanism of intestinal adaptation.93 
Dietary components supply continual signals inducing the expression of genes that 
influence intestinal adaptation.105 The amount and type of dietary fat consumed can influence 
intestinal function.106 Carbohydrates can induce the intestinal adaptation response by 
increasing hexose transporter levels in order to increase sugar absorption.107 Alterations in the 
amount of ingested protein induce adaptations in the transport of non-essential amino 
acids.108 Biliary acids solubilise fat and participate in complex hormone metabolism by 
activating nuclear receptors, which control the transcription of genes also involved in glucose 
metabolism, and the cell surface receptor TGR5, which modulates energy expenditure in 
muscle and adipose cells. TGR5 has been shown to be expressed by enteroendocrine GLP-1-
secreting L-cells. TGR5 activation by biliary acids results in intestinal secretion of GLP-1, thus 
improving post-prandial tolerance to insulin in mice, which might have implications for T2D 
treatment (Knop, 2010).109 TGR5, GPR119, and GPR120 are G protein-coupled receptors known 
to mediate the release of GLP-1 by L-cells.110-113 
The proglucagon gene encodes two hormones with important functions and opposite 
effects on glucose homeostasis: glucagon, which is expressed in pancreatic islets, and GLP-1, 
which is expressed in the bowels. The tissue-specific regulation of proglucagon expression 
remains poorly understood. In endocrine cell lines, the glucagon promoter is stimulated by 
beta-catenin, which is the main effector of the Wnt signalling pathway. GLP-1 synthesis and 
mRNA expression are activated by the inhibition of glycogen synthase kinase 3β, which is the 
main negative modulator of the Wnt pathway. In addition to demonstrating a specific 
mechanism for the regulation of proglucagon expression in intestinal endocrine cells, this 
study suggests that tissue-specific expression of the factors TF and TF-4 plays a role in the 
diverse Wnt signalling pathways.114 
Several hormones, such as glucocorticoids and the growth hormones IGF-1, EGF, 
keratinocyte growth factor (KGF), leptin, ghrelin, and GLP-2, can modify intestinal shape and 
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function. It is clear that genes regulating cell cycle, proliferation, differentiation, and apoptosis 
are important components of the adaptation process (Drozdowski et al., 2009).97 Several 
studies in humans and laboratory animals showed that after massive resection of the proximal 
small intestine, the remaining ileum exhibits morphological and functional adaptation in an 
attempt to preserve nutritional health by increasing ileal absorption of dietary nutrients. The 
authors of these studies concluded that the ileal adaptation mechanisms for peptide 
absorption are mediated by cell proliferation, i.e., villus hyperplasia and intestinal dilatation, 
which serves to increase the absorption surface.115 
Gastrointestinal epithelial cells are under constant regenerative pressure. To maintain 
homeostasis, there must be a balance among cell apoptosis, senescence, proliferation, and 
differentiation. The maintenance of this balance is attributed to gastrointestinal stem cells. 
These cells are able to replicate and give rise to cells identical to themselves and to cells that 
will differentiate into each of the different cell types present in this tissue.116 Small numbers of 
intestinal stem cells (between one and three) are found at the bottom of each of the 
Lieberkühn crypts, which are the invaginations that make up the intestine’s proliferative 
component. These cells give rise to a transient population of progenitor cells, which divide 
quickly while migrating along villi towards the bowel lumen. During migration, these cells 
commit to one of three different cell lineages: secretory (goblet cells), absorptive 
(enterocytes), or enteroendocrine. This is a continual process in which the most differentiated 
cells are replaced at the top of the villi every four or five days. Another type of secretory cell, 
called Paneth cells, differentiates at the bottom of the crypts (Figure 2).117 
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Figure 2. Intestinal epithelial cell types. A) One villus with one of the crypts contributing to its formation. Stem 
cells and Paneth cells are located at the crypt bottom. Above these cells are the multiplying progenitor cells, and 
higher up are the differentiated cells (absorptive, goblet, and enteroendocrine). B) The four types of 
differentiated cells.
118 
 
Enteroendocrine cells (EECs) comprise approximately 1% of all gastrointestinal tract 
cells, and although they are sparse, they are essential regulators of digestion, intestinal 
motility, appetite, and metabolism. How the relative proportions of individual subtypes and 
the endocrine compartment itself are maintained in this epithelium under rapid and 
constant renewal remains unclear (May and Kaestner, 2010).119 There are at least 14 
different types of EECs; each type of EEC secretes one or more hormones, such as GLP-1 
and GLP-2, or hormone-like substances that are released directly in the lamina propria and 
diffuse through the capillary vessels.119,120 EECs are polarised, with projections extending 
towards the intestinal lumen containing chemoreceptors sensitive to several classes of 
nutrients and other compounds present in the bowel contents. The base of these cells is 
close to capillary vessels and nerve endings, and they contain secretory vesicles with 
peptides secreted by cells in response to stimuli received by chemoreceptors. Secreted 
peptides act as classic hormones, travelling through the blood stream to act on receptors in 
distant organs, and as neuromodulators, acting on receptors expressed by autonomic nerve 
endings close to the peptide secretion site.121 Mechanisms regulating enteroendocrine cell 
differentiation are important during embryonic development and for the constant renewal 
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of the intestinal epithelium in the adult. The identification of transcription factors and DNA 
regulating elements that contribute to the specific genetic profile of each cell type is 
increasing the understanding of the different networks controlling the spatial and temporal 
activation of enteroendocrine differentiation programmes.122 EECs secrete several 
regulatory molecules that control physiological and homeostatic functions, mainly post-
prandial secretion and motility, and act as sensors of lumen contents.123 Although EECs 
secrete transcriptional regulators, they differentiate from pluripotent stem cells located in 
crypts. Their origin is therefore endodermal as with all epithelial mucosa cell types.124-126 
The Wnt signalling pathway plays an important role in the proliferative activity of 
the normal intestinal crypt.127 The Lgr5/GPR49 gene is only expressed in the stem cell 
compartment located at the crypt bottom, demonstrating that all epithelial lines derive 
from Ldr5-expressing intestinal stem cells.125 EEC spatial orientation along the crypt-villus 
axis is known to be closely associated with differentiation. Although most EECs differentiate 
and migrate towards the villus top, a recent study showed that a small EEC subpopulation 
that migrates towards or remains at the crypt bottom expresses stem cell markers and 
post-mitotic endocrine markers.128 A fourth type of secretory cell, referred to as tuft cells, 
was recently described. The differentiation of tuft cells depends on the transcription factors 
Atoh1/Math1 but not on other factors, distinguishing them from EECs, Paneth cells, and 
goblet cells. These cells are the main source of endogenous intestinal opioids, and they are 
the only type of epithelial cell expressing cyclooxygenase enzymes, suggesting an important 
role in intestinal epithelial physiopathology.129  
The Notch signalling pathway plays a crucial role in enteroendocrine differentiation. 
Notch is a transmembrane receptor protein that mediates cell-to-cell communication and 
coordinates a signalling cascade. Notch receives signals at the cell surface and functions in 
the nucleus to regulate gene expression.130 In mammals, the main components of this 
pathway are ligands (Delta and Jagged), receptors (Notch 1, 2, 3, and 4), and a transcription 
factor (RBP-Jk) that activates the target genes. Ligand interaction promotes proteolytic 
cleavage of Notch, thus releasing the Notch intracellular domain from the cell surface.131 
Intracellular Notch is transported to the nucleus, where it interacts with RBP-Jk to form a 
complex that binds and activates the promoters of hairy/enhancer of split (HES) gene family 
members. Hes1 or another HES family member then represses bHLH pro-endocrine 
transcription factors such as neurogenin 3 (Ngn3) by binding their promoters or enhancers 
(Figure 3).119,132,133  Hes1 is crucial for maintaining a reservoir of undifferentiated endocrine 
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precursors. Hes1-deficient mice have a greater number of serotonin-, cholecystokinin 
(CCK)-, proglucagon-, somatostatin-, and gastric inhibitory peptide (GIP)-producing cells in 
their bowels.132 
 
Figure 3. Participation of the Notch signalling pathway in endocrine cell differentiation. The Delta ligand is 
upregulated in differentiating endocrine cells. It binds to Notch in neighbouring non-endocrine cells, resulting in 
release of IC Notch, which is transported to the nucleus and interacts with RBP-Jk to activate target genes, such 
as Hes1, that inhibit bHLH pro-endocrine transcription factors such as Ngn3.
119
 
 
A major function of Notch is to mediate lateral inhibition between adjacent cells, 
preventing neighbouring cells from adopting the same fate.130-134 This function is evident in the 
findings that normal gastrointestinal epithelium never contains two adjacent EECs and that the 
loss of Notch function results in excess EECs. Notch signalling controls the differentiation 
programme directed by bHLH transcription factors to select individual EECs from the 
multiplying cell precursors.132-135 In addition to its role in the initial decisions that determine 
epithelial lineage, Notch signalling is also important in the final stages of differentiation, during 
which it plays a role in fine tuning the number of cells of each different enteroendocrine cell 
type. After the initial choice between the secretory and absorptive lineages, EEC fate is 
decided differently from that of other secretory cells (goblet and Paneth cells) through 
different components of Notch signalling, including Ngn3 and BETA2/NeuroD.132,136-139 
Loss-of-function studies in rats have shown that three bHLH pro-endocrine 
transcription factors, Math1 (also known as ATOH1), neurogenin 3 (Ngn3), and NeuroD, 
contribute to enteroendocrine cell differentiation.136,137,139,140 These transcription factors 
function sequentially, with one factor activating another to control the initial specification and 
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final differentiation of EECs.119 Math1 is necessary for the initial specification of all three 
intestinal secretory lines (goblet, Paneth, and EEC).138 Later on, expression of lineage-specific 
transcription factors, such as Sox9 for Paneth cells, Klf4 for Goblet cells, and Ngn3/NeuroD for 
EECs, is necessary.136,141,142 
 
Figure 4. Overview of enteroendocrine differentiation in the intestinal epithelium. Lgr5-expressing stem cells in the 
crypts give rise to the four intestinal epithelial cell types. Expression of Math1 is restricted to the secretory lineage, 
and Hes1 is restricted to the absorptive lineage. After this initial specification is established, lineage-specific 
transcription factors, such as Sox9 for Paneth cells, Klf4 for goblet cells, and Gf1/Ngn3/NeuroD for EECs, are 
necessary for differentiation into each specific secretory lineage.
119
 
 
Some studies show that intestinal precursors preferentially differentiate into 
enterocytes in the intestine of adult Math1 knockout rats, thus confirming the importance of 
this gene in maintaining the balance between enterocytes and EECs.143 In mice and humans, all 
intestinal EECs require Ngn3,136 which acts downstream of the Math 1 transcription factor. 
Ngn3 is a bHLH transcription factor that is activated on embryonic day 11.5.144 Its expression 
persists in the adult bowels and the glandular portion of the stomach.136 
Genetic analyses of NeuroD provided the first link between Notch signalling and EEC 
differentiation.139 In contrast to Ngn3, NeuroD expression is restricted to a subgroup of 
secretin-producing EECs.139,145 NeuroD acts downstream of Ngn3, as demonstrated by the lack 
of NeuroD expression in Ngn3-deficient mice.146 Notch signalling also controls the transcription 
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of Hes1, which encodes a bHLH transcriptional repressor that inhibits the activity of the bHLH 
transcriptional activators mentioned above.147 Hes1 is crucial for maintaining pro-endocrine 
reservoirs in an undifferentiated state. Several bHLH factors are up-regulated in rats in the 
absence of Hes1, resulting in early differentiation of enteroendocrine subtypes and high 
numbers of serotonin-, CCK-, proglucagon-, somatostatin-, and GIP-positive cells in the 
intestine.132   
Ngn3 and NeuroD specify the differentiation of EECs such as L-cells, in which Px4 and 
Pax6 play important roles in final differentiation.148 A diet rich in oligofructose, a non-digestible 
carbohydrate, was shown to double the number of GLP-1-producing L-cells in the proximal 
colon of rats through a mechanism involving up-regulation of Ngn3 and NeuroD. This study 
suggests that the final products of oligofructose fermentation, such as acetate, propionate, 
and butyrate, might be involved in the induction of L-cell differentiation. Butyrate is thought to 
regulate intestinal cell differentiation, as it was shown in vitro to increase the expression of the 
glucagon gene in immortalised L-cells. Moreover, butyrate infusion in the colon in vivo 
increases proglucagon and GLP-1 levels.149,150 
The transcription factors Foxa1 and Foxa2 are expressed throughout the 
gastrointestinal epithelium from embryo to adult. Mice lacking these factors also lack GLP-1- 
and GLP-2-expressing cells (L-cells), and they have reduced numbers of somatostatin-
expressing D-cells and PYY-expressing L-cells. The mRNA levels of glucagon, somatostatin, PYY, 
and the transcription factors Isl-1 and Pax6 were reduced in the small intestine of these 
animals, demonstrating that Foxa1 and Foxa2 are involved in the network of transcription 
factors regulating enteroendocrine lineage differentiation.151 
Transcription factors other than bHLH factors also seem to play important roles in EEC 
differentiation. In addition to the early EEC differentiation observed in Hes1-deficient animals, 
Pax4, Pax6, Nkx2.2, and Isl-1 genes were activated in the intestine.132 Instead of controlling EEC 
global differentiation like bHLH genes, these factors seem to play important roles in the fine 
control of specification decisions among enteroendocrine populations.119 LIM homeodomain 
genes encode a family of transcription regulating proteins involved in the control of several 
aspects of embryonic development and are responsible for some human diseases. Islet-1 (Isl-1) 
is expressed in gastrointestinal epithelium on approximately embryonic day 10, and in adults, 
its expression is restricted to EEC subgroups. Expression analysis suggests that Isl-1 might play 
an important role in the final differentiation and/or maintenance of mature enteroendocrine 
subtypes in the gastrointestinal epithelium.152 
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In the adult intestine, the zinc-finger transcription factor Gfi-1 is mainly found in 
crypts. Its expression is restricted to neuroendocrine lineages, and it acts downstream of 
Math1 in the differentiation process. Gfi-1 is a transcriptional repressor that acts in secretory 
lineage differentiation, specifically in the selection between enteroendocrine progenitors and 
other lineages (goblet and Paneth). Expression of Gfi-1 was detected in adult small intestine 
and colon crypts and villi. Gfi-1 co-localises with Math1, Ngn2, serotonin, and chromogranin A, 
but not with goblet and Paneth cells markers. These data suggest a model for intestinal 
epithelial differentiation in which Gfi-1 expression must be abolished for normal 
differentiation of goblet and Paneth cell progenitors (Figure 5). Alternatively, Gfi-1 might only 
be expressed in Math1/Ngn3-positive enteroendocrine precursors, whose production 
increases in the absence of Gfi-1, and serve to inhibit the production of goblet and Paneth cells 
from adjacent progenitors.140 
 
Figure 5. Model of intestinal epithelial cell differentiation. Stem cells give rise to highly proliferative multipotent 
progenitors that use Notch signalling to select Hes1- or Math1-expressing cells. Hes1-expressing cells differentiate 
into absorptive enterocytes, and Math1-expressing cells are the secretory lineage progenitors. Next, these 
progenitors co-express Gfi-1, which selects between goblet and Paneth cell progenitors (green) and 
enteroendocrine precursors (brown). Enteroendocrine precursors express Ngn3 and Gfi-1, which continues to be 
expressed in a subgroup of mature EECs.
140 
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Another zinc-finger protein, Insm1 or IA-1, is found in proliferating cells, many of which 
co-express NeuroD1 and chromogranin A.153 Insm1 has been shown to control the 
differentiation of specific intestinal enteroendocrine lineages and acts downstream of Notch 
and Ngn3 after the initial specification of enteroendocrine precursors.119 Several homeobox 
genes, including Isl-1, Pdx1, Nkx6.1, and Nkx2.2, have also been shown to participate in EEC 
differentiation.154 
Two paired box (Pax) genes, Pax 4 and Pax 6, are linked to pancreatic and intestinal 
endocrine cell differentiation.155,156 Deletion of Pax4 in the duodenum disrupts the 
differentiation of serotonin-, secretin-, CCK-, GIP-, and PYY-expressing cells; however, there is 
no significant reduction in the number of EECs in the ileum and colon of Pax4-deficient mice. 
There is a severe reduction of somatostatin- and gastrin-expressing cells in the distal stomach 
of Pax6-deficient mice; however, serotonin-expressing cells are not affected. The number of 
GIP-expressing cells in the duodenum of Pax6-deficient mice is reduced.157 Pax6 is crucial for 
proglucagon gene expression in intestinal epithelium. It is expressed in intestinal EECs and 
binds to G1 and G3 elements in the proglucagon promoter to activate its transcription.158,159 
Pax6 might also bind to the promoter and induce production of PC 1/3 pro-hormone 
convertase, an enzyme essential for the conversion of proinsulin into insulin160 and of 
proglucagon into GLP-1.43 Proglucagon processing is accomplished by PC1 in L-cells and by PC2 
in pancreatic alpha cells to produce glucagon. Published data suggest that these tissue-specific 
processing mechanisms are due to differential expression of PC1 and PC2.113,161,162 GIP, another 
important incretin, might be expressed alone or together with GLP-1. Cells expressing GIP and 
GLP-1 are Pax6- and Pdx1-positive, and cells expressing only GLP-1 are Pax6-positive and Pdx1-
negative. This suggests that the presence of Pdx1 determines whether gastrointestinal L-cells 
will co-express GIP.163 
Most Nkx6.1-expressing cells also express serotonin, and some express gastrin. Nkx6.1 
is not expressed in Pdx1-deficient mice, indicating that Pdx1 acts upstream of Nkx6.1 in 
enteroendocrine differentiation.164 Some enteroendocrine hormone-producing intestinal 
populations are reduced in Nkx2.2-deficient mice, including serotonin-, CCK-, GIP-, and gastrin-
producing cells; however, the number of ghrelin-expressing cells is greater, and the numbers 
of Paneth cells, goblet cells, and enterocytes are unaltered. It seems that Nkx2.2 functions 
upstream of Pax6 in regulating the fate of intestinal cells, as Pax6 mRNA and protein levels are 
reduced in Nkx2.2-deficient cells. Specification of ghrelin-expressing cells is thought to occur at 
the expense of other intestinal enteroendocrine cells; however, the total number of EECs 
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remains the same.165 Nkx6.3 knockout mice show a severe and selective reduction in gastrin-
secreting G-cells and an increase in somatostatin-secreting D-cells; however, these animals 
express normal levels of the Pdx1, Pax6, and Ngn3 transcription factors, which are needed for 
G-cell development.166 These results suggest that Nkx6.3 acts independently from other 
transcription factors in G-cell differentiation.119 
GATA transcription factors regulate proliferation, differentiation, and gene expression 
in several organs. In the small intestine, they are needed for crypt cell proliferation, secretory 
lineage differentiation, and gene expression in absorptive enterocytes. GATA4 is expressed in 
the proximal region in 85% of the small intestine and regulates the jejuno-ileal gradient of 
gene expression in absorptive enterocytes. GATA6 is co-expressed with GATA4, but it is also 
expressed in the ileum. Deletion of GATA6 in the ileum causes decreased crypt cell 
proliferation, reduces the number of Paneth cells and EECs, increases the number of crypt 
goblet cells, and alters the expression of specific genes in absorptive enterocytes. Deletion of 
GATA4 and GATA6 in rats results in a jejunum and ileum phenotype almost identical to that of 
the GATA6-deficient ileum, suggesting that GATA4 and GATA6 share some functions.167 
GATA4 is a zinc-finger transcription factor involved in jejunum gene expression. 
GATA4-deficient mice exhibit a dramatically decreased ability to absorb dietary cholesterol and 
fat. A study comparing global gene expression profiles in wild-type jejunum and ileum and 
GATA4-deficient jejunum demonstrated a 53% decrease in the expression of jejunum-specific 
genes and a 47% increase in the expression of ileum-specific genes in GATA4-deficient jejunum 
samples. Changes included decreased expression of mRNA encoding lipid and cholesterol 
transporters and increased expression of mRNA encoding proteins involved in bile absorption. 
This study showed that GATA4 is crucial for jejunum function and plays an essential role in the 
determination of jejunal versus ileal identity. It has been shown that GATA4 or GATA6 is 
necessary for secretory progenitors to commit to a neuroendocrine lineage.167-169 
Immunohistochemical analysis of mouse small intestine revealed that GATA4 is only expressed 
in villus enterocytes. GATA5 was not detected in enterocytes, but it was detected in other 
lineages. High levels of GATA6 were only detected in the neuroendocrine lineage. Together, 
these results suggest that GATA transcription factors may play different roles in the 
differentiation and/or allocation and maintenance of small intestine lineages.179  
Some transcription factors and signalling molecules regulate the expression of the 
glucagon gene. The homeoprotein Cdx-2 activates the glucagon gene promoter in pancreatic 
and intestinal proglucagon-producing cell lineages.171 The Pax-6 protein158 and the kinase A 
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signalling pathway172 are involved in the regulation of glucagon gene expression in pancreatic 
and intestinal glucagon-producing cell lineages, primary pancreatic islets, and intestinal cell 
cultures.114 
Studies of intestinal adaptation have examined genes possibly involved in this process 
using differential display polymerase chain reaction (DD-PCR) and cDNA microarray. 
Examination of the patterns of gene expression in animals during the adaptation process has 
revealed that some metabolism-related genes are increased at least two-fold after resection. 
Changes in the expression of genes encoding ion channels, transport proteins, transcriptions 
factors, DNA-binding proteins, receptors, and cytoskeleton proteins were also observed.173,174 
One study using DD-PCR showed that adaptation after resection results from the up-regulation 
of genes not previously related to the adaptation response. Genes that exhibited differential 
regulation after resection were divided into three categories: amino acid transport, protein 
transport, and signal transduction molecules. This same study suggested that analyses using 
reverse transcriptase polymerase chain reaction (RT-PCR) can more precisely define the 
magnitude of the adaptation response.93 
To study adaptation after 50% resection of the mouse intestine, cDNA microarrays 
were used to characterise the expression of individual genes and global gene expression 
patterns in the remaining ileum. The analysis of these microarrays revealed changes in the 
expression of several genes, including those involved in cell cycle regulation, apoptosis, DNA 
synthesis, and transcriptional regulation. Expression patterns were consistent with the 
increase in cell proliferation and apoptosis observed during intestinal adaptation; however, 
verification by RT-PCR and Northern blot are still necessary.173 Another study examined gene 
regulation after resection in mice using cDNA microarrays and showed that 27 genes were 
altered after resection; these genes included sprr2, which increased almost five-fold and had 
not previously been linked to intestinal adaptation.174 
Very little is known about what guides region-specific expression of hormones in the 
bowels. Despite the discovery of the function of transcription factors important for 
neuroendocrine cell differentiation, it is still not known how these factors direct and control 
gene expression in the different enteroendocrine cell types. Nor is it known to what degree 
these transcription factors control hormone expression in adults.119 
The differentiation mechanism of L-cells and the genetic and/or environmental factors 
that might influence the proliferation rate of this intestinal cell subtype, which is crucial for 
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maintaining normoglycaemia, remain unknown. Thus, comparison of intact and interposed 
ileum in terms of the differential expression of genes related to the differentiation of intestinal 
stem cells into each of the intestinal epithelial lineages, and specifically to the differentiation 
of neuroendocrine GLP-1-producing L-cells, is essential for the study of ileal interposition as a 
possible surgical treatment of T2D. 
2. AIMS 
Overall 
To assess the effects of isolated ileal interposition on intestinal stem cells of rats with diet-
induced glucidic dysmetabolism. 
Specific 
To investigate changes in the relative expression of genes involved in intestinal stem 
cell differentiation into enteroendocrine cells after isolated ileal interposition. 
To analyse changes in the number and function of L-cells after isolated ileal 
interposition. 
3. METHODS 
3.1. Research Ethics Committee 
This research project will be presented to the Experimental Research Ethics Committee 
of the Federal University of São Paulo – São Paulo School of Medicine (UNIFESP/EPM). 
3.2. Experimental procedures 
Experimental procedures will be performed according to guidelines in the manual 
“Care and Handling of Laboratory Animals”, Lapchick, Mattaria, Ko; Atheneu, 2009, CDD 
636.0885. 
All animals will be provided the same diet and will be subjected to surgery when they 
become dysmetabolic. Blood samples will be collected from all animals on the days of surgery 
and euthanasia for biochemical analysis. After euthanasia, samples will be collected from the 
interposed and remaining ileum of the interposition group and from the jejunum and ileum of 
the control group. These samples will be analysed using molecular biology and 
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immunofluorescence techniques to compare changes in the small intestine segment under 
study relative to the characteristic endocrine pattern of the ileum. 
3.3. Sample 
Twenty male Wistar – 2BAW heterogeneous male rats (Rattus norvegicus albinus) aged 
12 weeks and weighing between 250 and 280 g will be used. The animals will be supplied by 
the Laboratory of Animal Experimentation at the Institute of Pharmacology and Molecular 
Biology of the Federal University of São Paulo – São Paulo School of Medicine (UNIFESP/EPM), 
where they will be housed throughout the study. 
Animals will be housed in individual cages and kept for 32 weeks at a controlled 
ambient temperature of 23  2 C, relative humidity of 55  15%, and automatic 12-hour light–
dark cycle (06:00 / 18:00) (Timer-Kienzle). 
For surgical procedures, animals will be randomly distributed into two groups 
according to the flowchart defined below: 
- Interposition Group (IG) – 10 animals subjected to ileal interposition  
- Control Group (CG) – 10 animals not subjected to any surgical intervention 
 
 
 
 
 
 
 
 
  
  
 Surgical interventions will be performed at post-natal week 28 (W28) or as soon as 
glucidic dysmetabolism is established. All animals will be monitored until euthanised in the 16th 
post-operative week, which will be equivalent to post-natal week 44 (W44).  
Sample
N ≥ 20
Ileal Interposition
Group
(IG)
N = 10
Control
Group
(CG)
N = 10
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3.4. Diet 
 Throughout the experiment, all animals will be provided a lipid-rich pelletised 
hypercaloric diet (HD) ad libitum in alternating cycles of four feed types (1, 2, 3, and 4) to 
stimulate intake. The experimental feed will be alternated every 24 hours, and non-ingested 
amounts will be measured. Consumption of these diets will promote obesity in animals, which 
will exhibit characteristics commonly associated with human obesity, such as insulin 
resistance, hyperglycaemia, hyperinsulinaemia, dyslipidaemia, and liver steatosis. All groups 
will have free access to water. 
 Experimental feeds 1, 2, 3, and 4 will be industrially prepared by Rhoster®, Araçoiaba 
da Serra – SP according to guidelines in Requirements of the Laboratory Rat recommended by 
the National Academy of Sciences and will consist of standard rat feed with protein, vitamin, 
and mineral supplements. Additional hyperenergetic ingredients used in hypercaloric 
experimental diets will be (in grams per kilogram): 
 - HD1 – standard ration, 355; toasted peanuts, 176; casein, 123; corn oil, 82; chocolate, 
88; corn biscuits, 176; and vitamins and minerals. 
 - HD2 – standard ration, 439; toasted peanuts, 218; casein 129; corn oil, 61; chips, 153; 
and vitamins and minerals. 
 - HD3 - standard ration, 371; toasted peanuts, 185; casein, 99; corn oil, 68; pasta, 185; 
grated cheese, 92; and vitamins and minerals. 
 - HD4 - standard ration, 359; toasted peanuts, 179; casein 105; corn oil, 80; condensed 
milk, 161; wafer biscuits, 116; and vitamins and minerals. 
 The macronutrient composition of the standard and hypercaloric-hyperlipidic 
experimental feeds prepared and analysed in the laboratory by Rhoster®, Araçoiaba da Serra – 
SP is described in Table 1. 
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Table 1 – Composition of standard and experimental diets 
Compounds Feed 
 Standard HD1 HD2 HD3 HD4 
Protein (%) 26 27 28 28 26 
Carbohydrate (%) 54 43 36 33 43 
Fat (%) 3 20 23 24 20 
Other (%)
* 
17 10 13 15 11 
Calories (Kcal/g) 3.5 4.6 4.6 4.6 4.6 
*
 - vitamins, minerals, humidity, ashes. 
 
3.5. Weight and ration intake curve  
 As soon as the clear period begins, the animals will be weighed twice per week on pre-
established days using appropriate high-precision scales (Filizola BP-6), and each animal’s 
weight in grams will be recorded. Feed intake will be recorded three times per week on pre-
established days; in each cage, the difference between offered and consumed feed will be 
calculated, and estimated daily feed intake will be expressed in grams. Weight and feed intake 
curves will be calculated for both groups throughout the study. 
3.6. Blood collection and laboratory tests 
 Six hours before blood collection and surgical procedures, animals in all groups will be 
subjected to fasting with access to water ad libitum. Blood will be collected for laboratory tests 
on the week 12 (W12), two weeks before surgery (W26), eight weeks before surgery (W36)  
and on the day of euthanasia during the 16th post-operative week (W44), after weighing and 
under anaesthesia. 
 In total, 0.5 mL of blood will be collected from each animal in tubes containing 5 μl of 
DPP-IV inhibitor (an enzyme that degrades GLP-1) by caudal vein puncture. The blood samples 
will then be centrifuged, and serum will be stored at -20°C until analysis of serum levels of 
active glucagon-like peptide-1 (GLP-1), glucagon, insulin, and other diabetes-related analytes. 
For this purpose, we will use the Milliplex® Magnetic-Metabolism (Rat Metabolic Disease, 
Genese, SP) simultaneous quantification method. 
 Ten minutes after blood collection, serum glucose will be measured with reagent strips 
on a glucometer (Kit Accu-Chek Advantage®). Next, the animals will be subjected to an insulin 
tolerance test (ITT). Regular insulin will be injected in the penian vein at a concentration of 1 
U/kg body weight. One drop of blood will be collected from the tail using a lancet 4, 8, 12, and 
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16 minutes after insulin injection for the detection of glycaemia. The results will be recorded 
for later analysis. 
 Serum glucose will also be measured weekly on pre-established days throughout the 
study (W14 to W44) using reagent strips and a glucometer (Kit Accu-Chek Advantage®). 
3.7. Anaesthesia, weighing, and antibiotic prophylaxis  
 Before the onset of anaesthesia, all animals will be weighed on high-precision scales 
(Filizola BP-6), and their weights will be recorded in grams. In both groups (IG and CG), general 
anaesthesia will be induced with halothane to collect tail blood. Dissociative anaesthesia will 
then be induced by simultaneously injecting the animals intramuscularly with Zoletil 50® 
(tiletamine+zolazepam) at a dose of 20 mg/kg and Fentanil® at a dose of 0.025 mg/kg to 
perform the insulin tolerance test and surgical intervention.170 
 Each animal will be maintained on spontaneous ventilation during the procedure, and 
the anaesthetic plane will be checked periodically every 45 minutes by assessing the auricular 
and interdigital reflexes, which are abolished during anaesthesia. When these reflexes 
reappear, one-third of the initial anaesthetic dose will be administered. The total amount of 
anaesthetics used will be recorded at the end of the surgical intervention. 
 Antibiotic prophylaxis will be performed by intramuscular injection of cefoxitin at a 
dose of 50 mg/kg body weight soon after anaesthesia for surgery. 
3.8. Surgical procedures 
 Rats in the IG group will be subjected to surgery upon developing diet-induced glucidic 
dysmetabolism, which should occur around 28 weeks of life (W28). All Halsted asepsis and 
antisepsis principles will be applied, and sterile microsurgical tools will be used.  
 The anaesthetised rats will be placed in horizontal dorsal decubitus on the surgical 
table with the legs and tail duly immobilised and secured with tape. Antisepsis of the 
abdominal area will be performed with chlorhexidine in an aqueous vehicle.   
 A sterilised fenestrated surgical drape will be placed on each animal’s abdominal area, 
and a 5-cm long median longitudinal incision will be made in the wall with a disposable scalpel 
containing a number 15 blade. 
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 The caecum will be identified in each IG animal and exposed together with the 
terminal ileum. Next, the small intestine will be sectioned perpendicularly in two areas 5 cm 
and 15 cm from the ileo-caecal transition, thereby producing a 10-cm segment of ileum. The 
ileum segment will be removed and wrapped in gauze moistened with 0.9% saline solution 
(Figure 6A). Next, the jejunum will be sectioned in an area 5 cm from the duodenum-jejunum 
transition (Figure 6A). The previously separated distal ileum segment will be interposed 
between the segments of sectioned jejunum in isoperistaltic position by means of 
enteroenteric anastomosis (Figure 6B). Next, anastomosis will be performed between the 
interposed ileum and the remaining ileum to re-establish the continuity of the digestive tube 
(Figure 6C). 
 
Figure 6 – Illustrative scheme of section and anastomosis areas in the Interposition Group. (A) Section of jejunum 
and the isolated ileal segment to be interposed (red). (B) Ileum interposed to jejunum. (C) Anastomoses.  
 
 No surgical intervention will be performed on the CG animals.  
 All intestinal anastomoses will be termino-terminal and will be performed with a total 
of 6 separated points using 7-0 polypropylene sutures pre-mounted on cylindrical needles.   
 After completion of the final revision surgery, the animals will be hydrated by 
intraperitoneal injection of 1.0 mL crystalloid solution (0.9% physiological saline) per 300 g 
body weight at 36°C. 
 Abdominal wall synthesis will be performed by monoblock continual suture of parietal 
peritoneum, muscle layer, and aponeurosis using 4-0 polyglactin sutures pre-mounted on 
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cylindrical needles. In the skin, continual suture with inverted stitches will be performed using 
4-0 polyglactin sutures pre-mounted on cylindrical needles. 
3.9. Postoperative assessment 
 Animals will be kept warm and observed until full recovery from anaesthesia, when 
they will be placed in individual cages and transported to the housing room in the same 
laboratory and under the same environmental conditions as before surgery. 
 Before recovery from anaesthesia, animals will be given analgesic by gavage (0.5 mL of 
3 g/mL dipyrone in water). Water will be reintroduced ad libitum as soon as animals recover 
from anaesthesia. Dipyrone (1 g/100 mL in water) will be given during the first 72 post-
operative hours. Access to food will be allowed 12 hours after surgery. 
 The animals will be assessed and monitored until the 16th post-operative week (W44). 
3.10. Euthanasia 
 On the 44th post-natal week, the fasting, anaesthesia, weighing, and blood collection 
for laboratory tests will be repeated. Euthanasia will then be performed by decapitation 
according to the guidelines of the Brazilian Society of Laboratory Animals Science/Brazilian 
College of Animal Experimentation – SCAL-COBEA. 
3.11. Study parameters 
- Body Weight: as soon as the clear cycle starts, each animal in each group (IG and CG) will be 
weighed on high-precision scales, and the weight will be recorded in grams (W1, W2, W3…, 
W32). 
- Feed Intake: all animals will be given feed diurnally at a known amount sufficient for their 
daily needs; three times per week, non-ingested feed will be weighed on adequate scales, and 
daily feed intake will be calculated from the difference between supplied and remaining feed.  
- Biochemical Tests: serum levels of active GLP-1 (GLP-1), glucose (GLI), insulin (INS), and 
glucagon (GLU) will be measured in all animals on week 12 (W12),  two weeks before surgery 
(W26), eight weeks after surgery (W36) and euthanasia (W44). 
- Insulin Resistance: on the days of surgery and euthanasia, insulin resistance (IR) will be 
calculated using the HOMA-IR indirect test (Homeostasis Model Assessment Insulin Resistance) 
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from the product of serum insulin (mU/mL), glycaemia (mg/mL), and the constant 0.05551 
divided by 22.5. 
- Insulin Tolerance Test (ITT): will be performed in all animals on the day of study onset (W12), 
two weeks before surgery (S26), eight weeks after surgery (W36), and euthanasia (W44). The 
rate of glucose removal will be calculated using the formula In2/t1/2; t1/2 will be calculated 
for glucose from the minimum slope of the regression curve during the phase of linear decay 
of serum glucose concentration using PRISMA software. 
3.12. Tissue collection  
 After euthanasia, the following fragments of intestinal tissue will be collected for 
histological analysis by immunofluorescence and gene expression analysis by molecular 
biology: 
 - Interposition Group: median segment of transposed ileum and segment adjacent to 
ileal anastomosis (ileum remaining in normal position) (Figure 7A). 
 - Control Group: ileum segment and jejunum segment (Figure 7B). 
 
Figure 7 – Illustrative scheme of tissue collection for analysis. (A) Interposition Group: interposed ileum segment 
(purple) and remaining ileum adjacent to ileal anastomosis (green). (B) Control Group: segment of jejunum (blue) 
and ileum (yellow). 
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3.13. Histological analysis by immunofluorescence 
 One-centimetre tissue samples for histological analysis by immunofluorescence will be 
cryopreserved in increasing sucrose concentrations (10% and 20% for 4 hours at 4°C and 30% 
for 12 hours at 4°C), frozen in liquid nitrogen, and kept at -80°C until analysis. Three- to five-
micron-thick sections will be cut from the tissues using a cryostat (Leica) and mounted on 
silanated slides (BMF). 
 To block nonspecific staining, the slides will be incubated in phosphate-buffered saline 
(PBS) pH 7.4 + 1% bovine serum albumin (BSA) for 30 minutes at room temperature. For 
binding with primary antibody, the slides will be incubated with specific antibody (anti-GLP-1 
and others, Abcam) diluted in 1% PBS/albumin buffer (Sigma A9647) for 1 hour at 37°C or for 
16-18 hours at 4°C in a humid chamber. Next, they will be washed three times with 1% 
PBS/albumin for 5-10 minutes and incubated with a fluorophore-conjugated secondary 
antibody (FITC, Rhodamine, or Alexa Fluor 488, Invitrogen) for 90 minutes at 4°C in a humid 
chamber following the manufacturer's instructions. After incubation, the slides will be washed 
three times with 1% PBS/albumin for 5-10 minutes and incubated with the second primary 
antibody, and the incubation and washing steps described above will be repeated. Finally, the 
slides will be incubated with 4',6-diamidino-2-phenylindole (DAPI, Invitrogen) for 30 minutes at 
37°C, mounted on 1% glycerol-coated microscopy slides, and stored refrigerated and protected 
from light until analysis. 
 Immunoexpression of GLP-1, an L-cell marker, and other relevant genes will be 
assessed under a fluorescence microscope using appropriate filters for each fluorochrome.  
3.14. Molecular biology: studying relative gene expression  
3.14.1. Preparation of total RNA  
 Collected segments (interposed and remaining ileum in the IG, jejunum and ileum in 
the CG) will be immediately immersed in RNA stabilisation reagent (RNAlater RNA Stabilization 
Reagent, Qiagen) and stored in tubes (RNAlater Tissue Protect Tubes, Qiagen) at -20°C 
according to the manufacturer’s instructions until analysis. 
 To isolate total RNA, we will homogenise each sample using QIAzol reagent (QIAzol 
Lysis Reagent, Qiagen) on a Polytron tissue processor. After precipitation with ethanol, total 
RNA will be isolated using a commercial kit (RNeasy Mini Kit, Qiagen), and genomic DNA will be 
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eliminated (RNase Free-DNase Set, Qiagen). Total RNA concentration and purity will be 
assessed by spectrophotometry and agarose gel electrophoresis. 
3.14.2. Synthesis of cDNA and fluorescence 
 To convert total RNA into DNA, cDNA will be synthesised using a cDNA synthesis kit 
(RT2 Easy First Strand Kit, Qiagen). Next, we will add reagents from the RT2 SYBR Green Master 
Mix kit (Qiagen) to the synthesised cDNA for fluorescent intercalator emission to allow 
detection and analysis of the relative expression of genes of interest. 
3.14.3. Real-time PCR  
 Samples will be subjected to real-time polymerase chain reaction (real-time PCR) using 
an ABI 7500 thermocycler (Applied Biosystems, USA) with 5 specific kits, one per analysed 
pathway (Stem Cells, Notch, Diabetes, Stem Cell Signalling, and Wnt) and a kit specially 
customised for this study (Enteroendocrine Differentiation). The complete list of genes to be 
analysed with each kit is described in the tables below. 
 
KIT RT
2 
Rat Stem Cell PCR Array (PARN-405) 
Família de Genes Genes 
Stem Cell Specific 
Markers 
Cell Cycle Regulators: Apc, Axin1, Ccna2, Ccnd1, Ccnd2, Ccne1, Cdc2a, Cdc42, Ep300, Fgf1, 
Fgf2, Fgf3, Fgf4, Myc, Notch2, Pard6a, Rb1. 
Chromosome and Chromatin Modulators: Gcn5l2, Hdac1, Hdac2, Myst1, Myst2, Rb1, Tert. 
Genes Regulating Symmetric/Asymmetric Cell Division: Dhh, Ihh, Notch1, Notch2, Numb, 
Pard6a. 
Self-Renewal Markers: Hspa9a, Myst1, Myst2, Neurog2, RGD1565646 (Sox2). 
Cytokines and Growth Factors: Bmp1, Bmp2, Bmp3, Cxcl12, Fgf1, Fgf2, Fgf3, Fgf4, Igf1, 
Jag1, LOC306312 (Gdf2), RGD1564178 (Gdf3). 
Genes Regulating Cell-Cell Communication: Dhh, Dll1, Gja1, Gjb1, Jag1. 
Cell Adhesion Molecules: Agc1, Apc, Bglap2, Cd4, Cd44, Cdh1, Cdh2, Catna1 (Ctnna1), 
Cxcl12, Ncam1. 
Metabolic Markers: Abcg2, Aldh1a1, Aldh2, Fgfr1. 
 
Stem Cell 
Differentiation 
Markers 
Embryonic Cell Lineage Markers: Actc1, Ascl2, Foxa2, Isl1, Ka15 (Krt15), Msx1, Myod1, Pdx1 
(Ipf1), T. 
Hematopoietic Cell Lineage Markers: Cd19, Cd3d, Cd3e, Cd4, Cd8a, Cd8b, Mme. 
Mesenchymal Cell Lineage Markers: Agc1, Alpi, Bglap2, Col1a1, Col2a1, Col9a1, Pparg. 
Neural Cell Lineage Markers: Cd44, Ncam1, Oprs1, S100b, Tubb3. 
 
Signaling Pathways 
Important for Stem 
Cell Maintenance 
Notch Pathway: Dll1, Dll3, Dtx2, Dvl1, Ep300, Gcn5l2, Hdac1, Hdac2, Jag1, Notch1, Notch2, 
Numb. 
Wnt Pathway: Adar, Apc, Axin1, Btrc, Ccnd1, Fzd1, Myc, Ppard, Wnt1. 
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KIT RT
2 
Rat Notch Signaling Pathway PCR Array (PARN-059) 
Família de Genes Genes 
Notch Signaling 
Pathway 
Notch Binding: Dll1, Jag1, Jag2.  
Notch Receptor Processing: Adam10, Ncstn, Psen1, Psen2, Psenen. 
Notch Signaling 
Pathway Target 
Genes   
Apoptosis Genes: Cdkn1a (p21Cip1/Waf1), Cflar (Cash), Ifng, Nfkb1.  
Cell Cycle Regulators: Ccnd1, Cdkn1a (p21Cip1/Waf1).  
Cell Proliferation: Cdkn1a (p21Cip1/Waf1), Il2ra, Stat6.  
Genes Regulating Cell Differentiation: Ccnd1, Nr4a2 (Nur77), Pparg.  
Neurogenesis: Fos, Hes5, Nr4a2 (Nur77).  
Regulation of Transcription: Fos, Fosl1 (Fra1), Hes1 (Hry), Hes5, Hey1, Ifng, Nfkb1, Nfkb2, 
Nr4a2 (Nur77), Pparg, Stat6.  
Others with Unspecified Functions: Cd44, Chuk (IKKa), Erbb2 (Her2), Il17b, Krt1, Map2k7 
(Jnkk2), Pdpk1 (Pdk1), Ptcra. 
Other Genes 
Involved in the 
Notch Signaling 
Pathway 
Apoptosis Genes: Gsk3b, Notch1, Notch2, Psen1.  
Cell Cycle Regulators: Ccne1, Cdc16, Figf (Vegfd), Gsk3b, Jag2, Notch2, Pcaf (Kat2b).  
Cell Growth and Migration: Jag2, Lrp5, Notch2, Psen1, Shh, Wisp1.  
Cell Proliferation: Ctnnb1, Figf, Gsk3b, Jag1, Jag2, Notch2, Numb, Pcaf (Kat2b), Shh.  
Genes Regulating Cell Differentiation: Ctnnb1, Dll1, Gsk3b, Jag1, Jag2, Notch1, Notch2, 
Notch3, Notch4, Runx1 (Aml1), Shh.  
Neurogenesis: Dll1, Heyl, Jag1, Notch2, Numb, Pofut1, Rfng, Zic2 (Hpe5).  
Regulation of Transcription: Aes (Grg5), Ctnnb1, Ep300, Gli1, Hdac1, Heyl, Hoxb4, Hr, Mycl1 
(Lmyc1), Ncor2, Notch1, Notch2, Notch3, Notch4, Pcaf (Kat2b), Rbpjl, Runx1 (Aml1), Tead1, 
Tle1. 
Other Genes with Unspecified Functions: Adam17 (Cd156b), Cbl, Gbp2, Il6st (Gp130), Lfng, 
Lmo2, Map1b, Mfng, Mmp7 (Matrilysin), Neurl (Neu1), Sel1l, Supt6h. 
Genes from 
Signaling Pathways 
that Crosstalk with 
Notch Signaling 
Sonic Hedgehog (Shh) Pathway: Gli1, Gsk3b, Shh, Smo, Sufu.  
Wnt Receptor Signaling Pathway: Aes (Grg5), Axin1, Ctnnb1, Fzd1, Fzd2, Fzd3, Fzd4, Fzd5, 
Fzd6, Fzd7, Gsk3b, Lrp5, Tle1, Wisp1, Wnt11. 
 
 
 
KIT RT
2 
Rat Diabetes PCR Array (PARN-023) 
Família de Genes Genes 
Receptors, 
Transporters & 
Channels: 
Adra1a, Adrb3, Aqp2, Ccr2, Cd28, Ceacam1, Ctla4, Gcgr, Glp1r, Icam1, Il4ra, Nsf, Rab4a, Sell 
(LECAM-1), Slc2a4 (GLUT4), Slc14a2, Snap23, Snap25, Stx4a, Stxbp1, Stxbp2, Stxbp4, 
Tnfrsf1a, Tnfrsf1b, Vamp2, Vamp3, Vapa. 
Nuclear Receptors: Ppara, Pparg 
Metabolic 
Enzymes: 
Ace, Acly, Parp1 (Adprt), Dpp4, Enpp1, Fbp1, G6pc, Gck, Gpd1, Gsk3b, Hmox1, Ide, Nos3, 
Pygl, Sod2 
Secreted Factors: Agt, Ccl5 (Rantes), Gcg, Ifng, Il6, Il10, Il12b, Ins1, Retn, Tgfb1, Tnf, Vegfa. 
Signal 
Transduction: 
Akt2, Dusp4, Igfbp5, Ikbkb (IKKbeta), Inppl1 (SHIP2), Irs1, Irs2, Mapk8 (JNK1), Mapk14 (p38 
MAPK), Pik3cd, Pik3r1, Ptpn1 (PTP-1B), Trib3 (Skip3). 
Transcription 
Factors: 
Cebpa, Foxc2, Foxg1, Hnf4a, Foxp3 (LOC317382), Neurod1, Nfkb1, Nrf1, Pdx1 (Ipf1), 
Ppargc1a, Srebf1, Tcf2 (HNF1b), Titf1 
Others Serpine1 (PAI-1), Ucp2. 
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KIT RT
2 
Rat Stem Cell Signalling PCR Array (PARN-047) 
Família de Genes Genes 
Pluripotency 
Maintenance 
Pathway 
Receptors: Il6st (Gp130), Lifr. 
Transcription Factor: Stat3. 
Fibroblast Growth 
Factor (FGF) 
Signaling Pathway: 
Receptors: Fgfr1, Fgfr2, Fgfr3, Fgfr4. 
Transcription Factor: Cdx2. 
Hedgehog Signaling 
Pathway: 
Receptors & Coreceptors: Ptch1, Ptchd2, Smo. 
Transcription Factors & Cofactors: Gli1, Gli2, Gli3, Sufu. 
Notch Signaling 
Pathway: 
Receptors & Coreceptors: Ncstn, Notch1, Notch2, Notch3, Notch4, Psen1, Psen2, Psenen. 
Transcription Factor: Rbpjl. 
TGFß Superfamily 
Signaling Pathway: 
Receptors & Coreceptors: Acvr1 (Alk2), Acvr1b, Acvr1c, Acvr2a, Acvr2b, Acvrl1 (Alk1), 
Amhr2, Bmpr1a (Alk3), 
Bmpr1b (Alk6), Bmpr2, Eng (Evi-1), Ltbp1, Ltbp2, Ltbp3, Ltbp4, Rgma, Tgfbr1 (Alk5), Tgfbr2, 
Tgfbr3, Tgfbrap1. 
Transcription Factors & Cofactors: Crebbp, E2f5, Ep300, Rbl1, Rbl2, Smad1, Smad2, Smad3, 
Smad4, Smad5, 
Smad6, Smad7, Smad9, Sp1, Zeb2. 
Wnt Signaling 
Pathway: 
Receptors: Fzd1, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, Fzd9, Lrp5, Lrp6, Vangl2. 
Transcription Factors & Cofactors: Bcl9, Bcl9l, Ctnnb1, Lef1, LOC679869 (Tcf7l2), Nfat5, 
Nfatc2, Nfatc3, Nfatc4, 
Pygo2, RGD1560225 (Nfatc1), Tcf3, Tcf7 
 
KIT RT
2 
Rat Wnt Signalling PCR Array (PARN-043) 
Família de Genes Genes 
WNT Signaling 
Pathways 
Canonical: Apc, Apc2_predicted, Axin1, Axin2, Bcl9_predicted , Csnk1a1, Csnk1d, Csnk2a1, 
Csnk2b, Ctnnb1, Dixdc1_predicted, Dkk1_predicted, Dkk3, Dkk4_predicted, Dvl1, Dvl2, 
Dvl3_predicted, Ep300, Fzd1, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7_predicted, Fzd9, Gsk3a, 
Gsk3b, Lef1, Lrp5_predicted, Lrp6_predicted, Nkd1_predicted, Nkd2_predicted, Ppp2ca, 
Ppp2r1a, RGD1308535_predicted (Pygo2), RGD1564947_predicted (PorcnD), Senp2, Sfrp1, 
Sfrp2, Sfrp4, Sfrp5_predicted, Tcfe2a, Tcf3_predicted, Tcf4, Tcf7_predicted, Wif1, Wnt1, 
Wnt10a_predicted, Wnt10b_predicted, Wnt2, Wnt2b, Wnt3, Wnt3a_predicted, Wnt4, 
Wnt6_predicted, Wnt7a, Wnt7b, Wnt8a_predicted, Wnt8b_predicted.  
Planar Cell Polarity (PCP): Daam1_predicted, Dvl1, Dvl2, Dvl3_predicted, Nkd1_predicted, 
Nkd2_predicted, Rhoa, Wnt9a_predicted, Wnt9b_predicted. 
Wnt/Ca+2: Fzd2, Wnt1, Wnt10a_predicted, Wnt10b_predicted, Wnt11, Wnt2, Wnt2b, 
Wnt3, Wnt3a_predicted, Wnt4, Wnt5a, Wnt5b, Wnt6_predicted, Wnt7a, Wnt7b, 
Wnt8a_predicted, Wnt9a_predicted, Wnt9b_predicted. 
WNT Signaling 
Negative 
Regulation:  
Apc, Apc2_predicted, Axin1, Axin2, Btrc (bTrCP), Ccnd1, Dkk1_predicted, Dkk3, 
Dkk4_predicted, Fbxw11_predicted, Fbxw2_predicted, Frzb (FRP-3), Kremen1, 
Lrp6_predicted, Nkd1_predicted, Nkd2_predicted, RGD1561440_predicted (Nlk), Senp2, 
Sfrp1, Sfrp2, Sfrp4, Sfrp5_predicted, Tle1_predicted, Tle2, Wif1. 
WNT Signaling 
Target Genes: 
Btrc (bTrCP), Ccnd1, Ccnd2, Ccnd3, Jun, Mitf, Myc, Pitx2 
Developmental 
Processes: 
Cell Fate: Ctnnb1, Dkk1_predicted, Dkk3, Dkk4_predicted, Wnt1, Wnt3, Wnt3a_predicted. 
Tissue Polarity: Fzd2, Fzd3, Fzd5, Fzd6. 
Cell Growth & Profileration: Apc, Apc2_predicted, Ccnd1, Ccnd2, Ccnd3, Ctnnb1, Ep300, 
Fgf4, Fzd3, Jun, Lrp5_predicted, Myc, Ppp2ca, Ppp2r1a, Wisp1, Wnt3a_predicted. 
Cell Migration: Apc, Apc2_predicted, Dkk1_predicted, Dkk3, Dkk4_predicted, Lrp5_predicted, 
Lrp6_predicted, Wnt1. 
Cell Cycle: Apc, Apc2_predicted, Btrc (bTrCP), Ccnd1, Ccnd2, Ccnd3, Ctnnb1, Ep300, Jun, Myc, Rhoa, 
Tcfe2a, Tcf3_predicted 
Cellular 
Homeostasis: 
Apc, Apc2_predicted, Fzd2, Jun, Myc 
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KIT RT
2 
Rat Customized Enteroendocrine Differentiation PCR Array 
Genes 
ATOH1 (ou Math1) 
Ngn3, BETA2/NeuroD, Pax4, Pax6, Nkx2.2, Nkx6.1, Isl-1, Insm1 (ou IA-1), Pdx1, CCK  
Foxa1, Foxa2 
Gfi-1 
GATA4 
GATA5 
GATA6 
Proglucagon, Glucagon, GLP-1, GLP1-r, GLP-2, PYY, TGR5, GPR-119, GPR-120, PC-1, GIP 
TCF-4, Glicentin, Oxyntomodulin 
Other genes related to enteroendocrine differentiation  
 
3.14.4. Gene expression 
 The relative expression of genes of interest will be analysed in real-time by using the 
PCR equipment software Abi Prism 7000 Sequence Detection System version 1.6 to compare 
gene expression levels among tissue fragments from the different groups of animals. 
 During real-time PCR, fluorescence increases with every PCR cycle until reaching a 
threshold where all samples can be compared. The threshold corresponds to the time-point 
used for fluorescence analysis. This time-point is defined by the researcher and must be within 
the range in which fluorescence generated by sample amplification becomes significantly 
higher than background fluorescence. 
 The threshold is defined during the PCR exponential phase, when the amount of 
product formed can be used to calculate the initial concentration of template strands (cDNA) 
amplified by the reaction. The exact cycle when fluorescence crosses the threshold is called 
the threshold cycle (Ct). More concentrated samples (with greater numbers of initial template 
strands) reach the threshold faster and have lower Ct values. When PCR efficiency is close to 
100%, the number of copies generated increases exponentially and doubles with each reaction 
cycle. 
 The number of initial template strands can be calculated from the Ct. The equation 
Ns=No(1+E)n describes exponential PCR amplification, where “Ns” in the number of template 
strands at a given reaction cycle, “No” is the number of initial template strands, “E” is 
efficiency of the amplification reaction, and “n” is the number of cycles. Assuming that 
reaction efficiency is 100% (log E=1) and “n” is a selected amplification point identical for all 
samples, we can calculate the number of initial template strands using the following equation: 
N0=Nsx2-Ct. 
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 The method of analysing gene expression by real-time PCR proposed here represents a 
relative quantification of genes of interest because it requires an endogenous control (a gene 
whose expression does not exhibit statistically significant variation among the analysed 
samples). Relative quantification of a given sample by real-time PCR results from the 
relationship between the Ct of the gene of interest (i) and the Ct of the endogenous control 
(e):  
Nsi=Noi x 2-Cti (gene of interest) 
Nse=Noe x 2-Cte (endogenous gene) 
 
Because Nsi/Nse is equal to the normalised number of molecules of the gene of 
interest relative to the number of endogenous control molecules that we will call X, and Nse 
and Nsi is a constant that we will name K, the equation becomes: 
X=K.2- Ct  
Relative quantification of gene expression is used to describe changes in the 
expression of a gene of interest in a group of samples relative to a control group. In this study, 
we will compare ileum and jejunum samples in their normal localisations with interposed 
ileum samples and with ileum samples from animals in the sham-treated group. Thus, the 
value of X will be measured under two different conditions, and by dividing the value of X 
under condition A by the value of X under condition B, we obtain 2- Ct , as shown by the 
following equation: 
 
This method will be used in our study to calculate the relative expression levels of 
genes of interest. The relative expression levels of genes of interest will be compared among 
the different segments from different groups of animals (IG ileum, SG ileum, CG jejunum, and 
ileum). 
3.14.5. Statistical analysis 
 The variables will be summarised for each study group using the pertinent descriptive 
statistics: absolute (n) and relative (%) frequency, or mean, standard deviation (s.d.), median, 
maximum, and minimum values. The data will be analysed using parametric or non-parametric 
tests according to the observed distribution. 
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 For normally distributed data, analysis of variance will be applied with two fixed 
factors: groups (4 levels: IG, SG, CG1, and CG2) and assessment time-point (3 levels: Week 12 
(W12), Week 20 (W20), and Week 28 (W28)). For the variables assessed weekly, the test will 
have 16 levels corresponding to each week. For non-normally distributed data, the Mann-
Whitney test will be applied to compare techniques within each assessment, and the Friedman 
test will be applied to related samples to compare variations within each technique. The 
presence of an association between qualitative variables will be assessed by the chi-squared 
test or Fisher’s exact test. The level of significance will be set to 0.05 (α = 5%), and p values 
lower than this value will be considered significant. 
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